Welcome to our dedicated page for Atrium Therapeutics news (Ticker: RNA), a resource for investors and traders seeking the latest updates and insights on Atrium Therapeutics stock.
Atrium Therapeutics develops RNA therapeutics designed for targeted delivery to heart tissue. The biopharmaceutical company focuses on precision cardiology programs for rare genetic cardiomyopathies, including candidates ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, and uses ligand-based targeting approaches with oligonucleotide-based therapies.
Recurring Atrium news covers RNA delivery-platform development, cardiology research collaborations, clinical and regulatory preparation, capital-structure updates and governance matters such as equity inducement grants. Company updates also include milestone activity under its global cardiovascular collaboration with Bristol Myers Squibb and public-company developments following Atrium's launch as an independent Nasdaq-listed issuer.
Atrium Therapeutics (Nasdaq: RNA) reported second quarter 2026 results and advanced its precision cardiology pipeline. FDA cleared the IND for ATR 1072, and Health Canada issued a No Objection Letter, enabling the Corventis Phase 1/2 trial in PRKAG2 syndrome, which is planned to enroll about 37 participants in two parts. Atrium also earned a second $15 million milestone under its global cardiovascular collaboration with Bristol Myers Squibb, to be recognized in third quarter 2026.
For Q2 2026, collaboration revenue was $3.0 million. R&D expenses were $15.3 million and G&A expenses were $10.3 million, leading to a net loss of $20.2 million. As of June 30, 2026, cash, cash equivalents and short‑term investments totaled $263.9 million. According to Atrium, this, including the BMS milestone, is expected to fund operations through mid‑2028.
Atrium Therapeutics (Nasdaq: RNA) announced it has earned a $15 million milestone payment from Bristol Myers Squibb (NYSE: BMY) after delivering a second lead RNA-based compound for an undisclosed cardiovascular indication under their global licensing and research collaboration.
According to Atrium Therapeutics, the BMS agreement includes eligibility for up to approximately $1.35 billion in research and development milestones, up to approximately $825 million in commercial milestones, and tiered royalties up to low double-digits on net sales. BMS will fund all future clinical development, regulatory and commercialization activities arising from the collaboration. Atrium is also advancing ATR 1072 for PRKAG2 syndrome into the Corventis Phase 1/2 trial following recent FDA IND clearance, and maintains a pipeline including ATR 1086 for PLN cardiomyopathy and two additional rare cardiomyopathy programs.
Atrium Therapeutics (Nasdaq: RNA) granted inducement equity awards on July 20, 2026 to one newly hired non-executive employee under its 2026 Employment Inducement Incentive Award Plan. The awards comprise options for 7,000 shares at $11.76 and 3,500 RSUs, each with multi-year vesting tied to continued service.
Atrium Therapeutics (Nasdaq: RNA) announced that the U.S. FDA has cleared its Investigational New Drug (IND) application for ATR 1072, enabling the company to begin the Corventis™ Phase 1/2 clinical trial in PRKAG2 syndrome, a rare genetic cardiomyopathy with no approved therapies targeting its root cause.
Corventis™ is an open-label, multicenter Phase 1/2 study in approximately 37 participants, assessing safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of ATR 1072. Part A will use multiple ascending doses to characterize safety and inform dose selection, while Part B is a single-arm expansion cohort at the recommended Phase 2 dose to further evaluate cardiac structure and function. Clinical site initiation is underway, with first enrollment expected by end of 2026 and initial proof-of-concept data anticipated in the second half of 2027.
Atrium Therapeutics (Nasdaq: RNA) granted equity awards under its 2026 Employment Inducement Incentive Award Plan to eight newly hired non-executive employees on June 20, 2026.
The employees received options for 66,000 shares at $12.66 per share and 33,000 RSUs, with multi-year time-based vesting schedules, approved under Nasdaq Listing Rule 5635(c)(4).
Atrium Therapeutics (Nasdaq: RNA) reported first quarter 2026 results and outlined key pipeline and corporate milestones following its February 27 spin-off and Nasdaq listing.
Q1 collaboration revenue was $19.6M, R&D expenses $16.7M, G&A expenses $20.3M, and cash stood at $267.8M, viewed as sufficient through proof-of-concept milestones.
Atrium earned a $15M milestone from Bristol Myers Squibb, advanced ATR 1072 toward an IND in 2H 2026, and plans an IND for ATR 1086 in 2027.
Atrium Therapeutics (Nasdaq: RNA) announced it earned a $15 million development milestone from Bristol Myers Squibb (NYSE: BMY) after delivering a development candidate for a cardiology indication under their global collaboration.
Under the deal Atrium is eligible for up to $1.35 billion in R&D milestones, up to $825 million in commercial milestones, and tiered royalties up to low double-digits; Bristol Myers Squibb will fund future clinical development, regulatory, and commercialization activities.
Atrium Therapeutics (Nasdaq: RNA) awarded inducement equity grants on April 20, 2026 to seven newly hired non-executive employees under a new 2026 Inducement Plan adopted in April 2026.
The Awards total 101,250 stock options (exercise price $14.30) and 50,625 restricted stock units. Options and RSUs vest 25% after one year, then monthly or annual installments thereafter, subject to continued service. The Board's Human Capital Management Committee approved the grants under Nasdaq Listing Rule 5635(c)(4).
Atrium Therapeutics (Nasdaq: RNA) launched on Feb 27, 2026 with approximately $270 million in cash to advance targeted RNA medicines for rare genetic cardiomyopathies. The company begins with two lead candidates: ATR 1072 (PRKAG2 syndrome) and ATR 1086 (PLN cardiomyopathy).
ATR 1072 is in IND-enabling studies with an IND targeted in H2 2026; ATR 1086 has CMC planned to support IND-enabling studies and is targeting an IND in 2027. Both programs could enter clinical trials pending supportive Phase 1 results.
Avidity Biosciences (Nasdaq: RNA) will present one oral and six poster presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference, March 8-11, 2026, in Orlando, Florida.
Presentations include 1-year Phase 1/2 EXPLORE44 del-zota data showing near normalization of creatine kinase and functional improvements in DMD44, multiple DM1 and FSHD studies, and the SAFARI44 Phase 3 design. Materials will be posted on the company publications page after the meeting.